DAR No 4. Roflumilast (Daxas®, Libertek®) in severe COPD

Content tools

Share it

Doubts on safety and questionable efficacy

This drug is taken orally and is authorized in a small group of patients.
It has only been compared to placebo in patients who were not correctly treated.
There are doubts on its clinical efficacy in the trials.
There is concern regarding safety issues: suicide, weight loss, and absence of data on use over more than one year.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *